

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

DISCLOSEABLE TRANSACTION IN RELATION TO CAPITAL CONTRIBUTION IN AND ACQUISITION OF 100% EQUITY INTEREST IN FENGSHUO BIO MEDICAL TECH AND 51% EQUITY INTEREST IN GUANGDONG KELV BIO MEDICAL TECH COMPANY LIMITED AND CAPITAL CONTRIBUTION TO OBTAIN 28% EQUITY INTEREST IN FENGYUAN HUAKE BIO TECH

Reference is made to the announcements dated 23 November 2015 (the “**2015 Announcement**”), 28 March 2018 (the “**March 2018 Announcement**”) and 6 September 2018 of Common Splendor International Health Industry Group Limited (the “**Company**”). Unless the context otherwise states, capitalised terms used in this announcement have the same meanings as those defined in the 2015 Announcement.

UPDATE ON COMPENSATION PROPOSAL

As disclosed in the March 2018 Announcement, based on the information then available to the Company, it was expected that Target Company No. 1 would not be able to meet the Guarantee Profit.

The Board announces that the Company is still in progress of negotiating with the counterparties with a view to reaching an alternative compensation proposal in relation to the shortfall in the Guaranteed Profit. The Company currently expects that the parties will be able to agree on a compensation proposal in or around the end of November 2018.

The Company will publish a further announcement to inform its shareholders and investors of its discussion with Mr. Zhao and the Vendor in respect of the compensation proposal before the end of November 2018 or when an agreement is reached on the compensation proposal, whichever is earlier.

By Order of the Board of
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 6 November 2018

As at the date of this announcement, the board of directors of the Company comprises Mr. Cheung Wai Kuen, Mr. Cheng Hau Yan and Mr. Ye Jiong Xian as executive Directors; Mr. Hou Kai Wen and Mr. Lin Jiang as non-executive Directors; and Mr. Lam Chi Wing, Mr. Mai Yang Guang, and Mr. Wong Yiu Kit, Ernest as independent non-executive Directors.